MA53188A1 - Composés aromatiques et leurs utilisations pharmaceutiques - Google Patents

Composés aromatiques et leurs utilisations pharmaceutiques

Info

Publication number
MA53188A1
MA53188A1 MA53188A MA53188A MA53188A1 MA 53188 A1 MA53188 A1 MA 53188A1 MA 53188 A MA53188 A MA 53188A MA 53188 A MA53188 A MA 53188A MA 53188 A1 MA53188 A1 MA 53188A1
Authority
MA
Morocco
Prior art keywords
diseases
phospholipid
prodrug
solvate
relates
Prior art date
Application number
MA53188A
Other languages
English (en)
Inventor
Tore Skjaeret
David Alan Fraser
Hilde Hermansen Steineger
Original Assignee
Basf As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Basf As filed Critical Basf As
Publication of MA53188A1 publication Critical patent/MA53188A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/21—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing ether groups, groups, groups, or groups
    • C07C65/28—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing ether groups, groups, groups, or groups having unsaturation outside the aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/46—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C63/00—Compounds having carboxyl groups bound to a carbon atoms of six-membered aromatic rings
    • C07C63/64—Monocyclic acids with unsaturation outside the aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/52—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C07C229/54—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/52—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C07C229/54—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C229/60—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring with amino and carboxyl groups bound in meta- or para- positions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/53—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • C07C233/54—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of a saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/62—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C63/00—Compounds having carboxyl groups bound to a carbon atoms of six-membered aromatic rings
    • C07C63/04—Monocyclic monocarboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/21—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing ether groups, groups, groups, or groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/32—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing keto groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/02—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen
    • C07C69/12—Acetic acid esters
    • C07C69/16—Acetic acid esters of dihydroxylic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne des composés de formule générale (i) : dans laquelle r1, r2, r3, r4, r5, r6 et r7 peuvent être choisis parmi différents substituants; n vaut 0, 1 ou 2; et x est un hydroxyméthyle ou un acide carboxylique ou un dérivé de celui-ci, tel qu'un carboxylate, ester carboxylique, glycéride, anhydride, phospholipide, carboxamide, phospholipide, ou un promédicament de celui-ci; ou un sel, solvate, solvate de ce sel ou promédicament pharmaceutiquement acceptable de celui-ci. La présente invention concerne également des compositions pharmaceutiques et des compositions lipidiques comprenant au moins un composé selon l'invention, ainsi que des composés destinés à être utilisés comme médicaments ou en thérapie, en particulier dans le traitement de maladies relatives au domaine des maladies métaboliques et hépatiques, telles que la stéatose hépatique non alcoolique et des maladies de la cholestase.
MA53188A 2018-10-11 2019-10-10 Composés aromatiques et leurs utilisations pharmaceutiques MA53188A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862744461P 2018-10-11 2018-10-11
PCT/IB2019/001139 WO2020074964A1 (fr) 2018-10-11 2019-10-10 Composés aromatiques et leurs utilisations pharmaceutiques

Publications (1)

Publication Number Publication Date
MA53188A1 true MA53188A1 (fr) 2021-12-31

Family

ID=68655570

Family Applications (1)

Application Number Title Priority Date Filing Date
MA53188A MA53188A1 (fr) 2018-10-11 2019-10-10 Composés aromatiques et leurs utilisations pharmaceutiques

Country Status (16)

Country Link
US (1) US12473249B2 (fr)
EP (1) EP3864001A1 (fr)
JP (2) JP2022504707A (fr)
KR (1) KR20210091150A (fr)
CN (2) CN120923343A (fr)
AU (2) AU2019358595B2 (fr)
CA (1) CA3112073A1 (fr)
CL (1) CL2021000846A1 (fr)
CO (1) CO2021006087A2 (fr)
EA (1) EA202190890A1 (fr)
IL (1) IL282134A (fr)
MA (1) MA53188A1 (fr)
MX (1) MX2021003750A (fr)
PH (1) PH12021550744A1 (fr)
SG (1) SG11202103011YA (fr)
WO (1) WO2020074964A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023065200A1 (fr) * 2021-10-21 2023-04-27 Givaudan Sa Composés organiques
WO2024206117A1 (fr) 2023-03-24 2024-10-03 Northsea Therapeutics B.V. Dérivés d'acide benzoïque destinés à être utilisés dans des méthodes de traitement d'une maladie hépatique associée à une insuffisance intestinale chez des enfants

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5210266A (en) * 1987-12-03 1993-05-11 Dainippon Pharmaceutical Co., Ltd. N-substituted mercaptopropanamide derivatives
WO1993021912A1 (fr) 1992-04-28 1993-11-11 Fresenius Ag Utilisation d'une emulsion contenant des acides gras omega-3 pour la fabrication d'un medicament administrable par voie parenterale, pour le traitement de maladies inflammatoires
IL158322A0 (en) 2001-04-18 2004-05-12 Prometic Biosciences Inc Medium-chain length fatty acids, glycerides and analogues as neutrophil survival and activation factors
MXPA03011558A (es) * 2001-06-12 2004-03-26 Wellstat Therapeutics Corp Compuestos para el tratamiento de desordenes metabolicos.
AU2003261935A1 (en) * 2002-09-06 2004-03-29 Takeda Pharmaceutical Company Limited Furan or thiophene derivative and medicinal use thereof
RU2356887C2 (ru) * 2003-02-06 2009-05-27 ДОМПЕ ФА.Р.МА.С.п.А. 2-арилуксусные кислоты, их производные и содержащие их фармацевтические композиции
DK1592416T3 (da) 2003-02-07 2009-04-20 Prometic Biosciences Inc Fedtsyrer med middel kædelængde, glycerider og analoger som stimulatorer af erythropoiesis
MXPA05008600A (es) * 2003-02-13 2005-11-04 Wellstat Therapeutics Corp Compuestos para el tratamiento de desordenes metabolicos.
JP5214880B2 (ja) 2003-07-25 2013-06-19 プロメティック、バイオサイエンシーズ、インコーポレーテッド 中鎖脂肪酸の金属塩の製造
KR100872204B1 (ko) * 2003-10-15 2008-12-09 오에스아이 파마슈티컬스, 인코포레이티드 이미다조피라진 티로신 키나제 억제제
WO2005054243A1 (fr) * 2003-12-05 2005-06-16 Actelion Pharmaceuticals Ltd Derives de diazabicyclononene et leur utilisation en tant qu'inhibiteurs de la renine
KR20070063507A (ko) 2004-09-03 2007-06-19 프로메틱 바이오사이언시즈 인코포레이티드 면역조절작용과 화학방어활성을 가진 치환된 퓨리닐 유도체및 단독 또는 중쇄 길이 지방산이나 글리세리드와의 혼합사용
MX2007003967A (es) 2004-10-01 2008-03-04 Prometic Biosciences Inc Alcoholes grasos con longitud de cadena media como estimuladores de hematopoyesis.
US8071580B2 (en) 2004-10-01 2011-12-06 Prometic Biosciences Inc. Medium-chain length fatty alcohols as stimulators of hematopoiesis
EP1836160A1 (fr) * 2004-12-24 2007-09-26 CTG Pharma S.r.l. Composes destines au traitement d'un syndrome metabolique
TW200724138A (en) * 2005-03-29 2007-07-01 Sk Corp Substituted carboxylic acid derivatives for the treatment of diabetes and lipid disorders, their preparation and use
EP1881950A1 (fr) 2005-05-09 2008-01-30 AstraZeneca AB Nouveaux composes i
GB0522433D0 (en) 2005-11-03 2005-12-14 Astrazeneca Ab Therapeutic agents
EP1987020B1 (fr) * 2006-02-15 2012-10-03 Sanofi Nouvelles aryldihydroisoquinolinones à substitution azacyclyle, leur procédé de préparation et leur utilisation comme médicaments
WO2008016007A1 (fr) 2006-07-31 2008-02-07 Meiji Seika Kaisha, Ltd. INHIBITEUR DE LA MÉTALLO-β-LACTAMASE
EP2136624A4 (fr) 2007-03-21 2011-11-30 Emisphere Tech Inc Agents d'apport d'acide benzoïque allyloxy et alkyloxy
CL2008001632A1 (es) * 2007-06-05 2009-10-16 Sanofi Aventis Compuestos derivados de acidos benzoilamino-indan-2-carboxilicos sustituidos, inhibidores del receptor cxcr5; composicion farmaceutica; y su uso en el tratamiento de efecciones fisiologicas inflamatorias, tales como artritis reumatoidea y asma.
CN101878028A (zh) 2007-11-02 2010-11-03 普罗米蒂克生物科学公司 作为肾保护剂的中链长度脂肪酸和甘油酯
NZ586249A (en) 2007-12-19 2012-05-25 Prometic Biosciences Inc A combination of medium-chain length fatty acids, salts or triglycerides, gemcitabine, and optionally erlotinib, for the treatment of pancreatic cancer
CN101969918A (zh) * 2008-03-13 2011-02-09 巴斯夫欧洲公司 二聚亚苄基丙二酸酯
EP2291182A1 (fr) 2008-05-13 2011-03-09 Genmedica Therapeutics SL Conjugués de salicylés utiles pour le traitement de troubles métaboliques
US8586607B2 (en) * 2008-07-28 2013-11-19 Syddansk Universitet Compounds for the treatment of metabolic diseases
PT2427416E (pt) 2009-05-04 2016-06-15 Prometic Pharma Smt Ltd Compostos aromáticos substituídos e seus usos farmacêuticos
SG175401A1 (en) * 2009-05-08 2011-12-29 Pronova Biopharma Norge As Polyunsaturated fatty acids for the treatment of diseases related to cardiovascular, metabolic and inflammatory disease areas
US9242987B2 (en) 2009-10-20 2016-01-26 Cellzome Limited Heterocyclyl pyrazolopyrimidine analogues as JAK inhibitors
EA020849B1 (ru) 2009-11-26 2015-02-27 Женфит Применение 1,3-дифенилпроп-2-ен-1-оновых производных для лечения заболеваний печени
TWI572352B (zh) 2012-03-01 2017-03-01 波麥堤克藥學Ｓｍｔ有限公司 用於製備具中鏈長度之脂肪酸的三酸甘油酯之方法
WO2013173441A2 (fr) * 2012-05-16 2013-11-21 Glaxosmithkline Llc Inhibiteurs d'homologue d'activateur de zeste 2
TWI742541B (zh) 2013-03-15 2021-10-11 英商邊緣生物科技有限公司 用於治療肺纖維化、肝纖維化、皮膚纖維化及心臟纖維化之經取代之芳族化合物
TWI689490B (zh) 2013-03-15 2020-04-01 英商邊緣生物科技有限公司 用於治療纖維化之經取代之芳族化合物及相關方法
WO2015179697A1 (fr) * 2014-05-21 2015-11-26 Taxis Pharmaceuticals, Inc. Composés pour le traitement d'infections bactériennes
WO2016054726A1 (fr) 2014-10-10 2016-04-14 Prometic Biosciences Inc. Composés aromatiques substitués et compositions pharmaceutiques pour la prévention et le traitement du diabète
GB2543478A (en) 2015-09-07 2017-04-26 Manchester Metropolitan Univ Glycomimetics
CN111936532B (zh) 2018-05-08 2024-03-12 株式会社艾迪科 化合物、潜伏性添加剂、组合物、固化物、固化物的制造方法及组合物的制造方法

Also Published As

Publication number Publication date
AU2019358595B2 (en) 2025-04-17
IL282134A (en) 2021-05-31
CN120923343A (zh) 2025-11-11
JP2024122966A (ja) 2024-09-10
CA3112073A1 (fr) 2020-04-16
JP2022504707A (ja) 2022-01-13
MX2021003750A (es) 2021-06-15
EA202190890A1 (ru) 2021-09-10
AU2019358595A1 (en) 2021-05-27
PH12021550744A1 (en) 2022-02-21
US12473249B2 (en) 2025-11-18
CN113166024A (zh) 2021-07-23
BR112021006907A2 (pt) 2021-09-08
CL2021000846A1 (es) 2021-11-12
SG11202103011YA (en) 2021-04-29
CO2021006087A2 (es) 2021-08-09
KR20210091150A (ko) 2021-07-21
EP3864001A1 (fr) 2021-08-18
WO2020074964A1 (fr) 2020-04-16
AU2025205518A1 (en) 2025-08-07
CN113166024B (zh) 2025-07-18
US20210380521A1 (en) 2021-12-09

Similar Documents

Publication Publication Date Title
MA33341B1 (fr) Acides gras polyinsaturés pour le traitement de maladies relatives au domaine des maladies cardiovasculaires, métaboliques et inflammatoires
MA44721A (fr) Inhibiteurs de mcl1 macrocycliques pour le traitement du cancer
MA40111B1 (fr) Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1
MA37762A1 (fr) Composés n-aryltriazole utilisés comme antagonistes de lpar
MA37764A1 (fr) Composés n-alkyltriazole utilisés comme antagonistes de lpar
MA33083B1 (fr) Nouveaux lipides contenant du soufre pour utilisation en tant que supplément alimentaire ou médicament
MA33105B1 (fr) Esters (1-phényl-2-pyridin-4-yl) éthyliques d'acide benzoïque en tant qu'inhibiteurs de la phosphodiestérase
MA32798B1 (fr) Acides naphtylacétiques
TN2009000138A1 (fr) Biaryl-ether-urees
MA29775B1 (fr) Derives de pyrazolone
MA34903B1 (fr) Derives de type azaindazole ou diazaindazole utilises comme medicaments
SK147097A3 (en) Fatty acid esters as bioactive compounds
MA32009B1 (fr) Nouveaux derives de pyrazolo [3,4-d]pyrimidine en tant qu'agents anticancereux
MA37765A1 (fr) Composés de pyrazole substitués utilisés comme antagonistes de lpar
MA29311B1 (fr) Derives d'isoxazolines et son nouveau procede de production
MA53188A1 (fr) Composés aromatiques et leurs utilisations pharmaceutiques
JPH08506347A (ja) 皮膚炎の治療のための３，４−ジアリールクロマン
US20100160427A1 (en) Method of treating vascular injuries induced by an excess of plasma lipids using combinations of vasoprotective agents
MA47082B1 (fr) Amides aromatiques d'acide carboxylique en tant qu'antagonistes des recepteurs bradykinin b1
MA62148B1 (fr) Inhibiteur de magl
MA68743B1 (fr) Composés et compositions pour le traitement d'états associés à l'activité du récepteur de lpa
FR2405067A1 (fr) Compositions pharmaceutiques contenant des derives monofonctionnels du psoralene pour le traitement des affections cutanees
MA57379B1 (fr) Modulateurs du recepteur alpha associe aux oestrogenes (err-alpha)
CA2366829A1 (fr) Nouveaux derives de morpholine, procede pour leur preparation et compositions pharmaceutiques les contenant
MA30567B1 (fr) Dérivés d'acide phénylacétique.